Antidepressant Screening
Antidepressant Screening - Related Videos
01:25
Antidepressant Drugs: Overview
0 Views •
2024
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23
Antidepressant Drugs: MAOIs and Other Agents
0 Views •
2024
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
0 Views •
2024
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
09:44
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
0 Views •
2015
Here we describe a cell-based reporter gene assay as a valuable tool to screen chemical libraries for compounds modulating post-transcriptional control mechanisms exerted through 3’ UTR.
08:50
Genetic Screens
0 Views •
2023
Genetic screens are critical tools for defining gene function and understanding gene interactions. Screens typically involve mutating genes and then assessing the affected organisms for phenotypes of interest. The process can be “forward”, where mutations are generated randomly to identify unknown genes responsible for the phenotypes, or it can be “reverse”, where specific genes are targeted for mutation to observe what phenotypes are produced.Here, JoVE reviews various types of genetic...
FAQs
A behavioral improvement should be linked to the specific endpoint being measured rather than treated as a general indicator of mood improvement. Changes in stress-coping behavior, motivation, activity, and social interaction may reflect different aspects of drug action. Examining several endpoints helps investigators determine whether a compound produces a consistent behavioral profile or affects only one domain.
Untreated groups provide a reference for baseline behavior and normal variation, while established-drug groups show whether the assay detects a response under the same conditions. Comparing a candidate with both groups helps distinguish treatment-associated changes from handling, testing, or environmental effects. The established-drug comparison also provides a practical benchmark for judging the magnitude of an observed response.
A dose-response assessment shows whether behavioral effects change as the administered amount increases or decreases. This information helps identify doses associated with measurable activity and reveals whether responses are consistent across conditions. Interpreting dose effects alongside endpoint-specific results can clarify a candidate’s behavioral profile and identify limitations that might be missed when only one dose is examined.
Behavioral assays provide preclinical evidence, but their findings represent selected experimental endpoints rather than the full complexity of depression or treatment response. A compound may alter activity, motivation, or stress-coping behavior without producing a broad antidepressant-like profile. For that reason, behavioral findings require interpretation with pharmacological and physiological data before candidates are advanced toward clinical testing.
A basic workflow includes selecting relevant behavioral endpoints, administering the test substance under controlled conditions, and comparing treated subjects with untreated and established-drug groups. Investigators then evaluate changes in the measured behaviors, examine dose-related patterns when available, and consider the consistency of effects across endpoints. This structured comparison supports a more reliable assessment than relying on a single observation.
The approach can assess stress-coping behavior, motivation, activity, and social interaction, depending on the research question and assay design. These endpoints provide complementary information about how a compound changes behavior under controlled conditions. Measuring more than one domain can reveal whether effects are broad or selective, helping investigators characterize candidates before integrating the results with other evidence.
In behavioral research, screening connects compound exposure with measurable changes in actions relevant to mood-related investigation. The resulting behavioral profiles help prioritize candidates for further study, compare responses with established treatments, and identify dose-related patterns or experimental limitations. When combined with pharmacological and physiological findings, the results can guide investigation of mood-related mechanisms and treatment development.